| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | disordered domain specific binding | 3.61e-05 | 39 | 33 | 3 | GO:0097718 | |
| GeneOntologyMolecularFunction | intracellularly gated calcium channel activity | 3.99e-04 | 18 | 33 | 2 | GO:0015278 | |
| GeneOntologyMolecularFunction | ligand-gated calcium channel activity | 1.20e-03 | 31 | 33 | 2 | GO:0099604 | |
| GeneOntologyMolecularFunction | calcium channel activity | 1.25e-03 | 129 | 33 | 3 | GO:0005262 | |
| GeneOntologyMolecularFunction | intracellularly ligand-gated monoatomic ion channel activity | 1.35e-03 | 33 | 33 | 2 | GO:0005217 | |
| MousePheno | enhanced avoidance learning behavior | 3.85e-05 | 5 | 28 | 2 | MP:0012313 | |
| MousePheno | enhanced passive avoidance behavior | 3.85e-05 | 5 | 28 | 2 | MP:0003999 | |
| Domain | Spectrin_repeat | 1.62e-05 | 29 | 32 | 3 | IPR002017 | |
| Domain | Spectrin/alpha-actinin | 2.19e-05 | 32 | 32 | 3 | IPR018159 | |
| Domain | SPEC | 2.19e-05 | 32 | 32 | 3 | SM00150 | |
| Domain | RIH_assoc | 4.25e-05 | 6 | 32 | 2 | PF08454 | |
| Domain | RIH_assoc-dom | 4.25e-05 | 6 | 32 | 2 | IPR013662 | |
| Domain | RIH_dom | 4.25e-05 | 6 | 32 | 2 | IPR000699 | |
| Domain | Ins145_P3_rcpt | 4.25e-05 | 6 | 32 | 2 | IPR014821 | |
| Domain | Ryanodine_recept-rel | 4.25e-05 | 6 | 32 | 2 | IPR015925 | |
| Domain | - | 4.25e-05 | 6 | 32 | 2 | 1.25.10.30 | |
| Domain | RYDR_ITPR | 4.25e-05 | 6 | 32 | 2 | PF01365 | |
| Domain | Ins145_P3_rec | 4.25e-05 | 6 | 32 | 2 | PF08709 | |
| Domain | Plectin_repeat | 5.94e-05 | 7 | 32 | 2 | IPR001101 | |
| Domain | Plectin | 5.94e-05 | 7 | 32 | 2 | PF00681 | |
| Domain | PLEC | 5.94e-05 | 7 | 32 | 2 | SM00250 | |
| Domain | MIR | 1.27e-04 | 10 | 32 | 2 | PS50919 | |
| Domain | MIR | 1.27e-04 | 10 | 32 | 2 | PF02815 | |
| Domain | MIR | 1.27e-04 | 10 | 32 | 2 | SM00472 | |
| Domain | MIR_motif | 1.27e-04 | 10 | 32 | 2 | IPR016093 | |
| Domain | Spectrin | 7.04e-04 | 23 | 32 | 2 | PF00435 | |
| Domain | Quinoprotein_ADH-like_supfam | 3.71e-03 | 53 | 32 | 2 | IPR011047 | |
| Domain | SH3 | 5.91e-03 | 216 | 32 | 3 | PS50002 | |
| Domain | SH3_domain | 6.22e-03 | 220 | 32 | 3 | IPR001452 | |
| Pubmed | Regulation of the type 1 inositol 1,4,5-trisphosphate receptor by phosphorylation at tyrosine 353. | 8.73e-07 | 2 | 33 | 2 | 14761954 | |
| Pubmed | Fyn can partially substitute for Lck in T lymphocyte development. | 2.62e-06 | 3 | 33 | 2 | 8934569 | |
| Pubmed | 2.62e-06 | 3 | 33 | 2 | 12754204 | ||
| Pubmed | 2.62e-06 | 3 | 33 | 2 | 28598420 | ||
| Pubmed | Intracellular calcium release channel expression during embryogenesis. | 2.62e-06 | 3 | 33 | 2 | 9986730 | |
| Pubmed | Ryanodine receptor calcium release channels: lessons from structure-function studies. | 5.23e-06 | 4 | 33 | 2 | 23413940 | |
| Pubmed | 5.23e-06 | 4 | 33 | 2 | 9607712 | ||
| Pubmed | 5.23e-06 | 4 | 33 | 2 | 19120137 | ||
| Pubmed | Intracellular calcium-release channels: regulators of cell life and death. | 8.72e-06 | 5 | 33 | 2 | 9124414 | |
| Pubmed | 1.31e-05 | 6 | 33 | 2 | 23463619 | ||
| Pubmed | 1.31e-05 | 6 | 33 | 2 | 20519450 | ||
| Pubmed | Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging. | 1.31e-05 | 6 | 33 | 2 | 25966694 | |
| Pubmed | IP3Rs are sufficient for dendritic cell Ca2+ signaling in the absence of RyR1. | 1.31e-05 | 6 | 33 | 2 | 16844763 | |
| Pubmed | 1.76e-05 | 591 | 33 | 6 | 15231748 | ||
| Pubmed | 1.83e-05 | 7 | 33 | 2 | 11860456 | ||
| Pubmed | Twist1 transcriptional targets in the developing atrio-ventricular canal of the mouse. | 4.78e-05 | 11 | 33 | 2 | 22815831 | |
| Pubmed | 6.02e-05 | 225 | 33 | 4 | 12168954 | ||
| Pubmed | E protein silencing by the leukemogenic AML1-ETO fusion protein. | 7.89e-05 | 14 | 33 | 2 | 15333839 | |
| Pubmed | 1.18e-04 | 17 | 33 | 2 | 20395553 | ||
| Pubmed | ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. | 3.02e-04 | 27 | 33 | 2 | 17525332 | |
| Pubmed | 3.17e-04 | 638 | 33 | 5 | 31182584 | ||
| Pubmed | 3.25e-04 | 28 | 33 | 2 | 25332179 | ||
| Pubmed | Gene expression in the developing mouse retina by EST sequencing and microarray analysis. | 3.32e-04 | 142 | 33 | 3 | 11812828 | |
| Pubmed | 3.74e-04 | 30 | 33 | 2 | 16454711 | ||
| Pubmed | 4.06e-04 | 152 | 33 | 3 | 34299191 | ||
| Pubmed | Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. | 4.12e-04 | 372 | 33 | 4 | 22939624 | |
| Pubmed | Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development. | 6.01e-04 | 38 | 33 | 2 | 30786075 | |
| Pubmed | 6.22e-04 | 415 | 33 | 4 | 16385451 | ||
| Pubmed | 6.66e-04 | 40 | 33 | 2 | 28386764 | ||
| Pubmed | 6.85e-04 | 182 | 33 | 3 | 15102471 | ||
| Pubmed | Aire's partners in the molecular control of immunological tolerance. | 8.43e-04 | 45 | 33 | 2 | 20085707 | |
| Pubmed | Huntingtin interacting proteins are genetic modifiers of neurodegeneration. | 8.62e-04 | 197 | 33 | 3 | 17500595 | |
| Pubmed | The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1. | 8.62e-04 | 197 | 33 | 3 | 20811636 | |
| GeneFamily | EF-hand domain containing|Plakins | 6.91e-05 | 8 | 29 | 2 | 939 | |
| Coexpression | GSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_DN | 4.91e-06 | 200 | 33 | 5 | M9408 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Fibroblasts|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.40e-06 | 157 | 33 | 4 | f086753b51860e23f1275bd75e8802d2a7d7b70a | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 8.10e-06 | 174 | 33 | 4 | 58300d64d3b6fd9ba1b6c87ea83b2777eb6be2f4 | |
| ToppCell | facs-Marrow-KLS-18m-Lymphocytic-early_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.47e-06 | 176 | 33 | 4 | 88ca2f83d8301633232735f39b0683efe49d0b86 | |
| ToppCell | facs-Marrow-KLS-18m-Lymphocytic-early_pro_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.47e-06 | 176 | 33 | 4 | 7292e014b8f697f0c2e9f47c48333de95cb44a69 | |
| ToppCell | CD8+_Memory_T_cell-CV-7|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster | 1.17e-05 | 191 | 33 | 4 | 9454f642c3621370fa23640b631301346b300950 | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.24e-05 | 194 | 33 | 4 | 0b9cd96fa0b616da7cc90e92ff71157e9bba518f | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 1.74e-04 | 147 | 33 | 3 | 94998bc40f5c08295cfe3bdcbe43f13b1e564b3d | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.77e-04 | 148 | 33 | 3 | 80470353e12599440f711b6e107730763376d04d | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligoastrocytoma-4|TCGA-Brain / Sample_Type by Project: Shred V9 | 1.81e-04 | 149 | 33 | 3 | ff472ad641efd655905e99a9a4cacd5245ab8854 | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8|bone_marrow / Manually curated celltypes from each tissue | 2.07e-04 | 156 | 33 | 3 | 1545169694f686d28648a68b552c2ae606599d66 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.23e-04 | 160 | 33 | 3 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.23e-04 | 160 | 33 | 3 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8|blood / Manually curated celltypes from each tissue | 2.31e-04 | 162 | 33 | 3 | b4535bcb3f469bc139e73f1122f4070013e5a1de | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-plasmacytoid_dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.48e-04 | 166 | 33 | 3 | 6e6075d0c913e2516083f6dcab21d5878bcef7a4 | |
| ToppCell | droplet-Lung-1m-Hematologic-myeloid-plasmacytoid_dendritic_cell|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.48e-04 | 166 | 33 | 3 | 1ca888ae8168707493f19ee52a89d7c70e6cb51d | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_KRT17|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.48e-04 | 166 | 33 | 3 | 739dfbe927f409821ff23aca6e47ebe78f57e859 | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-Plasmacytoid_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.48e-04 | 166 | 33 | 3 | 4fbe44e0aea197893614cd55f83119aa0f73ee53 | |
| ToppCell | droplet-Lung-1m-Hematologic-myeloid-plasmacytoid_dendritic_cell-plasmacytoid_dendritic|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.48e-04 | 166 | 33 | 3 | 4cba4ca1aa2321b9ef7cd230932b890d2434a252 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.52e-04 | 167 | 33 | 3 | a6ff7a3d9b80839c0efa91658836812e868561fa | |
| ToppCell | Mild/Remission-B_naive-4|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.61e-04 | 169 | 33 | 3 | c3a6179a64589a370108fea809b157839347759c | |
| ToppCell | 10x5'v1-week_17-19-Hematopoietic-HSC/MPP_and_pro-ELP|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.66e-04 | 170 | 33 | 3 | a50e558d0b38100ccbdccb90647fe93e85bffd86 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-04 | 171 | 33 | 3 | 6a0fafb8fd9fc7671618eeb2bf528ce8ce86b794 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-04 | 171 | 33 | 3 | e02b5831768dbb1b68998b672e55c9680ab0cc86 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_KRT17|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.75e-04 | 172 | 33 | 3 | adc09c4d1b63fe84150516beb692db1e7f7ac980 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 2.80e-04 | 173 | 33 | 3 | efb8072475000888efe088d00e870c56ffad4172 | |
| ToppCell | (6)_Endothelial_cells-(6)_Endothelial-E|(6)_Endothelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 2.85e-04 | 174 | 33 | 3 | 4a1b67ce5ea353b3f81f59fa57da07668146afca | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-Tfh|blood / Manually curated celltypes from each tissue | 2.90e-04 | 175 | 33 | 3 | d7e24ac683ff36f7ce3d1151353d3d4a6f2b63bf | |
| ToppCell | droplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.95e-04 | 176 | 33 | 3 | 749b47eac5436fa34e0d243ffbc6f1897f4e431e | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.99e-04 | 177 | 33 | 3 | 9edfb50856f5e10672ab194ce0076d6a190e64de | |
| ToppCell | nucseq-Epithelial-Epithelial_Airway-Basal/Suprabasal|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.99e-04 | 177 | 33 | 3 | cbad1a23851151dbef01ea2af960e6f0944f838b | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.09e-04 | 179 | 33 | 3 | 87a69f9f83b8f0c028a4874acb238f2e079bf51f | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.09e-04 | 179 | 33 | 3 | dcaf2191134a586d50ebaf67dcf5b815b54a722b | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.09e-04 | 179 | 33 | 3 | 6e965e424eebef50f0202cff75f458be395cfca1 | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 180 | 33 | 3 | bf8d13d4db1af55b8c9fe16aaccf8743e000e005 | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 180 | 33 | 3 | 839defb40f7cfb2711e9025194de636533f51bcd | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 180 | 33 | 3 | 82965ed1b72a1873c24dd4553d39681596057316 | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.15e-04 | 180 | 33 | 3 | df60970520fba2ac0639faa54096766d07418ca4 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Epithelial-neuro-epithelial-M/X_cells_(MLN/GHRL+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.20e-04 | 181 | 33 | 3 | cb17c904ab86d56dd30cac9b61acbb3b76f84ded | |
| ToppCell | COPD-Epithelial-Basal|World / Disease state, Lineage and Cell class | 3.20e-04 | 181 | 33 | 3 | 6d8a886b4afe729f8a05b9c0f4ea9375de735da4 | |
| ToppCell | 10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8|Liver / Manually curated celltypes from each tissue | 3.20e-04 | 181 | 33 | 3 | f2315414e714ac86211546a935660c4be6e85f1b | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.30e-04 | 183 | 33 | 3 | 8a799807fbf24456a9811e0c64068187940a2f71 | |
| ToppCell | COPD-Epithelial-Basal|COPD / Disease state, Lineage and Cell class | 3.30e-04 | 183 | 33 | 3 | 0f760e393edc91009bf6c7e02eeac039a1dfb4ed | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.35e-04 | 184 | 33 | 3 | bd786db4dc4edae6d5cfc0b69901983dea19f729 | |
| ToppCell | CV-Moderate-7|Moderate / Virus stimulation, Condition and Cluster | 3.41e-04 | 185 | 33 | 3 | a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.46e-04 | 186 | 33 | 3 | 84ba666237c18189d7e7556bd92dd953af733c00 | |
| ToppCell | CV-Moderate-7|CV / Virus stimulation, Condition and Cluster | 3.46e-04 | 186 | 33 | 3 | 8571956890fc9894d766ba294a28e376b4aba428 | |
| ToppCell | 343B-Endothelial_cells-Endothelial-E|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 3.46e-04 | 186 | 33 | 3 | 080e56113b89138277a2bd2eabddfa6cd1a18b61 | |
| ToppCell | 343B-Endothelial_cells-Endothelial-E-|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 3.46e-04 | 186 | 33 | 3 | dae6a98963c78bf7518ebab8dc02f173c3b0f7f7 | |
| ToppCell | pdx-Tumor_cells-T5|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 3.52e-04 | 187 | 33 | 3 | 7e376831a11ee72ed87abcdac631ca46ae29c250 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 3.57e-04 | 188 | 33 | 3 | ab9b725d6e0cdab8e9ddda6dee09e14730e9a578 | |
| ToppCell | -Unknown-Endothelial-Myofibroblast| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.57e-04 | 188 | 33 | 3 | 6468fa95ad0395395301115286f2d8c0df5d3882 | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.57e-04 | 188 | 33 | 3 | 9858940c616e43441644c5a3bea8d832ee4daf79 | |
| ToppCell | -Unknown-Endothelial| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.57e-04 | 188 | 33 | 3 | 7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6 | |
| ToppCell | LA-13._Vascular_Smooth_Muscle|LA / Chamber and Cluster_Paper | 3.57e-04 | 188 | 33 | 3 | 34e1b074a3995aa46ab194eb45115d76d1a5514d | |
| ToppCell | -Unknown| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.57e-04 | 188 | 33 | 3 | 9cb718bfe1358c6fd842f096e228eb0abb9aefc6 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T5|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 3.57e-04 | 188 | 33 | 3 | b070a0667f1ee9b825b267b6c389b7c42fc436f9 | |
| ToppCell | T_cells-GZMK+_CD8+_T_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 3.63e-04 | 189 | 33 | 3 | e2ca075aedf7c370ab4ede6272254ffd06cbcdec | |
| ToppCell | Control-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class | 3.68e-04 | 190 | 33 | 3 | 7f3f419fffe02934b6f27b697f7a6401072491ed | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.68e-04 | 190 | 33 | 3 | 49e09cdb843b3d889a06a811aa5affae68b25a75 | |
| ToppCell | 10x3'2.3-week_17-19-Lymphocytic_B-B_lineage-pro_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.74e-04 | 191 | 33 | 3 | 40813c397f533c2f4a6359a77757f736b6d9e07d | |
| ToppCell | B_cell_maturation-CD34+_pre-plamsa|B_cell_maturation / Lineage and Cell class | 3.74e-04 | 191 | 33 | 3 | 4ee160a863d4fb9c4c9449633b9f337db8871992 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group | 3.80e-04 | 192 | 33 | 3 | 8b86db2ebe0199fee0e9800566a619a24bfdeed5 | |
| ToppCell | human_hepatoblastoma-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 3.80e-04 | 192 | 33 | 3 | 916fbec1c7ab7969bda711886ac88e877e30c280 | |
| ToppCell | facs-Aorta-Heart-3m|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.80e-04 | 192 | 33 | 3 | 1ccc47792edf9ee23501c8e2165d11271636b66a | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 3.80e-04 | 192 | 33 | 3 | 47646d7e4990be85072987f92bf18d52f8da752e | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.80e-04 | 192 | 33 | 3 | 5c7e8b80b44d9ce55c797cdf8267ac5382e26cac | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.86e-04 | 193 | 33 | 3 | e09387af84d2a0a526e54d4793e6e06c6739db53 | |
| ToppCell | Control-Stromal-Myofibroblast|Stromal / Disease state, Lineage and Cell class | 3.86e-04 | 193 | 33 | 3 | 5896242f713ae5fd1a4ebb63827f15d7279dced2 | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-Gen_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.86e-04 | 193 | 33 | 3 | 6e1982d089a9de628e6006d23ff78a223fbd9f47 | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-bulge_keratinocyte|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.86e-04 | 193 | 33 | 3 | eba3c70701b051bc1ed1f4db9270cb27a77ffc3e | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary-CAP1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.86e-04 | 193 | 33 | 3 | ad3f4fcc8e2816d696cbcde744dc16500e51ccac | |
| ToppCell | severe-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.86e-04 | 193 | 33 | 3 | 9337bc93e3904c7fc7c93c328518bcd6453b1e8c | |
| ToppCell | Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.92e-04 | 194 | 33 | 3 | 68004855b23fe1e31e8452d70effabc78a4a0bd3 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Lymphoid-NK-NK-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.92e-04 | 194 | 33 | 3 | 3211d89440a6f4a9b3d4cfb755890816944242ec | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-outer_bulge|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.92e-04 | 194 | 33 | 3 | 5d30d3d41d5f19cdf3077cc609aa2738762cb8c5 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.92e-04 | 194 | 33 | 3 | a44be2f021cfdd0fcdc698c3f04d66db7a1aa6c2 | |
| ToppCell | IPF-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class | 4.03e-04 | 196 | 33 | 3 | 8f0f72ead06abe02b575e443552eacc2151077ef | |
| ToppCell | Endothelial-capillary_endothelial_cell_(Cap1)|World / Lineage, Cell type, age group and donor | 4.03e-04 | 196 | 33 | 3 | 0ce3ed27d2b9276390952652c17a8d6de13add36 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 4.09e-04 | 197 | 33 | 3 | fdb92985f7df0c280b87d3e43c2394e70786a2c7 | |
| ToppCell | T_cells-Treg_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 4.09e-04 | 197 | 33 | 3 | de5448fcdf4e433fc167496413abe5d0c8a5c6d8 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.09e-04 | 197 | 33 | 3 | adb4e27d73ae2e6a39d212c0ead3ac0ad62d9131 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-04 | 199 | 33 | 3 | 1e693d7bb481bf03a943b460a69787229625d7b1 | |
| ToppCell | Tracheal-NucSeq-Immune_Lymphocytic-T-T_CD3-NKT|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.22e-04 | 199 | 33 | 3 | d3dc52e1f0040763888f951a7c047db4a329a653 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-04 | 199 | 33 | 3 | 8bf8d7cd774479f065bbbbcb5a4bd1aa91aa0d85 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-04 | 199 | 33 | 3 | 6977f939ddbc47d4921f36c0a61a205259fe1284 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-04 | 199 | 33 | 3 | 0c060ef64341659f4b1247d0264ac12e53a7e12e | |
| ToppCell | Tracheal-NucSeq-Immune_Lymphocytic-T-T_CD3|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.22e-04 | 199 | 33 | 3 | 4be4527f351b701438a8bcb738229a06dbf8bc96 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-04 | 199 | 33 | 3 | fbd39d34636137d1b877dd8815d58f124990136b | |
| ToppCell | Neuronal-Excitatory-eE(FEZF2_SLC17A7)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.28e-04 | 200 | 33 | 3 | 501cd2b4e55444fc5fdd93ebbcfc0616442b110b | |
| ToppCell | control-Epithelial|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 4.28e-04 | 200 | 33 | 3 | f95bbb94e51ac28b1995026c599ec3a34e012916 | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 4.28e-04 | 200 | 33 | 3 | dccec522ab0d7fff62ad6273b02aa9022dbbb8eb | |
| ToppCell | LPS_anti-TNF-Endothelial-Endothelial-Gen_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 4.28e-04 | 200 | 33 | 3 | a2b9d1cd291d17abddc3ee2e242121412c864b8b | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.28e-04 | 200 | 33 | 3 | b68d212159b9d04866ba02ff55c35be247805eec | |
| ToppCell | control|World / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 4.28e-04 | 200 | 33 | 3 | 97f36d2c197e03d93a1fc59949d77ae90f6e6a9a | |
| ToppCell | Neuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)---L5-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.28e-04 | 200 | 33 | 3 | 046a3a4d7e4d84ee4252a695ffd4a6aee8b77070 | |
| ToppCell | Neuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.28e-04 | 200 | 33 | 3 | 893cc7f6b9794da90aa0c9d721b8647dc97201cd | |
| ToppCell | Neuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.28e-04 | 200 | 33 | 3 | 3d677f13e429abc805a52ec2b8f36c703f511569 | |
| ToppCell | NS-control-d_0-4-Epithelial|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.28e-04 | 200 | 33 | 3 | d014959891893b6d3854a471fba1dc50c6625a0a | |
| ToppCell | Neuronal-Excitatory|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.28e-04 | 200 | 33 | 3 | 4409065bc7aa995354c71e0f9d6f3726cf393d6b | |
| ToppCell | 5'-Airway_Nasal|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.28e-04 | 200 | 33 | 3 | f6e967738b4f7b173d6e9977e305f77380dd6c8a | |
| Drug | N-cyclopentyl-N-cyclobutylformamide | 5.09e-06 | 79 | 33 | 4 | CID005287890 | |
| Drug | manidipine | 1.06e-05 | 95 | 33 | 4 | CID000004008 | |
| Drug | Cyclic ADP-Ribose | 1.22e-05 | 4 | 33 | 2 | ctd:D036563 | |
| Drug | CNS 1145 | 1.47e-05 | 33 | 33 | 3 | CID000190902 | |
| Drug | IHC-64 | 1.47e-05 | 33 | 33 | 3 | CID000162753 | |
| Drug | lamotrigine | 2.34e-05 | 116 | 33 | 4 | CID000003878 | |
| Drug | [[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate | 4.26e-05 | 7 | 33 | 2 | CID009547999 | |
| Drug | Br2BAPTA | 4.26e-05 | 7 | 33 | 2 | CID003081001 | |
| Drug | Cinildipine | 7.30e-05 | 56 | 33 | 3 | CID000002752 | |
| Drug | nilvadipine | 8.97e-05 | 60 | 33 | 3 | CID000004494 | |
| Drug | PCB 95 | 9.10e-05 | 10 | 33 | 2 | CID000038012 | |
| Drug | IAA-94 | 9.43e-05 | 61 | 33 | 3 | CID000003667 | |
| Drug | lercanidipine | 1.04e-04 | 63 | 33 | 3 | CID000065866 | |
| Drug | lavendustin A | 1.06e-04 | 171 | 33 | 4 | CID000003894 | |
| Drug | R 478 | 1.11e-04 | 11 | 33 | 2 | CID000084223 | |
| Drug | 8-amino-cADPR | 1.11e-04 | 11 | 33 | 2 | CID003081323 | |
| Drug | gallopamil | 1.25e-04 | 67 | 33 | 3 | CID000001234 | |
| Drug | AC1L2AC7 | 1.36e-04 | 69 | 33 | 3 | CID000068733 | |
| Drug | Ipratropium bromide [22254-24-6]; Down 200; 9.8uM; HL60; HG-U133A | 1.56e-04 | 189 | 33 | 4 | 1769_DN | |
| Drug | CAS 298-57-7 | 1.61e-04 | 73 | 33 | 3 | CID000002761 | |
| Drug | ethosuximide | 1.68e-04 | 74 | 33 | 3 | CID000003291 | |
| Drug | Ethynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 1.76e-04 | 195 | 33 | 4 | 3346_UP | |
| Drug | Dobutamine hydrochloride [49745-95-1]; Down 200; 11.8uM; PC3; HT_HG-U133A | 1.79e-04 | 196 | 33 | 4 | 6286_DN | |
| Drug | Trimipramine maleate salt [521-78-8]; Up 200; 9.8uM; MCF7; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 3342_UP | |
| Drug | Adrenosterone [382-45-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 1.86e-04 | 198 | 33 | 4 | 5464_UP | |
| Drug | Pepstatin A [26305-03-3]; Up 200; 5.8uM; MCF7; HT_HG-U133A | 1.90e-04 | 199 | 33 | 4 | 3264_UP | |
| Drug | Thyroxine (L) [51-48-9]; Up 200; 5.2uM; MCF7; HT_HG-U133A | 1.90e-04 | 199 | 33 | 4 | 3249_UP | |
| Drug | nisoldipine | 1.96e-04 | 78 | 33 | 3 | CID000004499 | |
| Drug | Fura-2AM | 2.04e-04 | 79 | 33 | 3 | CID000105091 | |
| Drug | FPL 64176 | 2.11e-04 | 15 | 33 | 2 | CID000003423 | |
| Drug | Gvapspat amide | 2.11e-04 | 15 | 33 | 2 | CID000125015 | |
| Drug | plakin | 2.27e-04 | 82 | 33 | 3 | CID000018752 | |
| Disease | Prostatic Neoplasms | 5.54e-05 | 616 | 33 | 6 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 5.54e-05 | 616 | 33 | 6 | C0376358 | |
| Disease | PR interval | 2.10e-04 | 495 | 33 | 5 | EFO_0004462 | |
| Disease | complex trait | 2.31e-04 | 271 | 33 | 4 | EFO_0010578 | |
| Disease | amyotrophic lateral sclerosis (implicated_via_orthology) | 5.17e-04 | 30 | 33 | 2 | DOID:332 (implicated_via_orthology) | |
| Disease | urate measurement, bone density | 5.83e-04 | 619 | 33 | 5 | EFO_0003923, EFO_0004531 | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 6.53e-04 | 152 | 33 | 3 | DOID:0060041 (implicated_via_orthology) | |
| Disease | pulmonary function measurement, forced expiratory volume | 7.88e-04 | 37 | 33 | 2 | EFO_0003892, EFO_0004314 | |
| Disease | Carcinoma, Transitional Cell | 9.68e-04 | 41 | 33 | 2 | C0007138 | |
| Disease | Huntington's disease (is_marker_for) | 1.61e-03 | 53 | 33 | 2 | DOID:12858 (is_marker_for) | |
| Disease | vascular endothelial growth factor measurement | 1.80e-03 | 56 | 33 | 2 | EFO_0004762 | |
| Disease | C-reactive protein measurement | 1.98e-03 | 1206 | 33 | 6 | EFO_0004458 | |
| Disease | psoriasis vulgaris | 2.13e-03 | 61 | 33 | 2 | EFO_1001494 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TMPWKCHSLEDYRKH | 331 | Q4VNC0 | |
| KEDHYVGHWKEGKMC | 1096 | Q96Q42 | |
| NCYNTKSHAHKMVKW | 1731 | Q92793 | |
| CEMHVYAQWKHAVKF | 1266 | Q8TDJ6 | |
| QSKCYEMEDVLKHHW | 981 | P15918 | |
| HHGEKMLESFCKWQH | 391 | Q8TE59 | |
| HIMDQHWKFCVECEE | 1856 | Q8N7Z5 | |
| IYTAWGEHCEHLSMK | 5351 | Q99102 | |
| MKCNCKYDGHRIWVH | 711 | P58215 | |
| FEEHIKEEHNMWHYL | 2636 | Q14643 | |
| KEEHNMWHYLCFIVL | 2641 | Q14643 | |
| DEWKHLDHALNCIME | 346 | O43439 | |
| HYKDLWDNKHVKMPC | 501 | Q86W56 | |
| IEAHMEAVHADWKEY | 291 | O60437 | |
| WCKTMVHTACKDLYH | 281 | Q86XP1 | |
| CMQKAQKYQWHVEDL | 4906 | Q9UPN3 | |
| MKKEHVLHCQFSAWY | 1 | O75794 | |
| SYLHCKWATMEELEK | 326 | Q8TD26 | |
| HDHDIIWTEAYMDSK | 481 | Q7Z3S7 | |
| DWDDMKGDHVKHYKI | 191 | P06241 | |
| VFHHWHSYMEDQKEK | 56 | Q8NEE6 | |
| INKYAEHSHDKWSMD | 2721 | Q92736 | |
| FTHWKHYMLLCAEEA | 356 | A8K8P3 | |
| KAQWEETVTYMTHCH | 91 | Q6ZMZ3 | |
| VSMCLEHLLFDHKYW | 131 | Q8TF17 | |
| NHVKSMWYPEIKHFC | 116 | O94844 | |
| QHYKHEDAKEMPLTW | 61 | Q7Z3I7 | |
| EWCRAMTKKYEHVDI | 386 | A8MU46 | |
| DMWYHLFKVSHEENI | 151 | Q9NYW1 | |
| DKKYTYTCLHWHHDM | 236 | Q8IWA0 | |
| HVMHAVCWQKYFEAV | 1161 | Q8IWV7 | |
| EYNKHAQLWMESTHC | 471 | Q9HBX9 | |
| HEHTYQDKEEVVLWM | 31 | Q9HD45 | |
| MWRSDLELQFKCYHH | 601 | Q9ULJ6 |